BIOCRYST PHARMACEUTICALS INC (BCRX) Stock Fundamental Analysis
USA - NASDAQ:BCRX - US09058V1035 - Common Stock
7.2 USD
+0.01 (+0.14%)
7.26 USD
+0.06 (+0.83%)
BCRX gets a fundamental rating of 4 out of 10. The analysis compared the fundamentals against 534 industry peers in the Biotechnology industry. Both the profitability and the financial health of BCRX get a neutral evaluation. Nothing too spectacular is happening here. BCRX is not valued too expensively and it also shows a decent growth rate.
1. Profitability
1.1 Basic Checks
In the past year BCRX has reported negative net income.
BCRX had a positive operating cash flow in the past year.
BCRX had negative earnings in each of the past 5 years.
BCRX had a negative operating cash flow in each of the past 5 years.
1.2 Ratios
BCRX's Return On Assets of -7.81% is amongst the best of the industry. BCRX outperforms 85.77% of its industry peers.
BCRX has a better Return On Invested Capital (15.29%) than 96.25% of its industry peers.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| ROA | -7.81% | ||
| ROE | N/A | ||
| ROIC | 15.29% |
ROA(3y)-35.62%
ROA(5y)-38.56%
ROE(3y)N/A
ROE(5y)N/A
ROIC(3y)N/A
ROIC(5y)N/A
1.3 Margins
BCRX has a Operating Margin of 9.72%. This is amongst the best in the industry. BCRX outperforms 92.13% of its industry peers.
BCRX has a better Gross Margin (97.00%) than 96.44% of its industry peers.
BCRX's Gross Margin has been stable in the last couple of years.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| OM | 9.72% | ||
| PM (TTM) | N/A | ||
| GM | 97% |
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3Y0.65%
GM growth 5Y1.2%
2. Health
2.1 Basic Checks
With a Return on Invested Capital (ROIC) just above the Cost of Capital (WACC), BCRX is creating some value.
Compared to 1 year ago, BCRX has more shares outstanding
BCRX has more shares outstanding than it did 5 years ago.
The debt/assets ratio for BCRX is higher compared to a year ago.
2.2 Solvency
Based on the Altman-Z score of -2.18, we must say that BCRX is in the distress zone and has some risk of bankruptcy.
BCRX has a Altman-Z score (-2.18) which is comparable to the rest of the industry.
BCRX has a debt to FCF ratio of 1038.46. This is a negative value and a sign of low solvency as BCRX would need 1038.46 years to pay back of all of its debts.
BCRX's Debt to FCF ratio of 1038.46 is amongst the best of the industry. BCRX outperforms 90.45% of its industry peers.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Debt/Equity | N/A | ||
| Debt/FCF | 1038.46 | ||
| Altman-Z | -2.18 |
ROIC/WACC1.79
WACC8.55%
2.3 Liquidity
A Current Ratio of 2.25 indicates that BCRX has no problem at all paying its short term obligations.
With a Current ratio value of 2.25, BCRX is not doing good in the industry: 71.72% of the companies in the same industry are doing better.
A Quick Ratio of 2.21 indicates that BCRX has no problem at all paying its short term obligations.
BCRX's Quick ratio of 2.21 is on the low side compared to the rest of the industry. BCRX is outperformed by 70.22% of its industry peers.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Current Ratio | 2.25 | ||
| Quick Ratio | 2.21 |
3. Growth
3.1 Past
BCRX shows a strong growth in Earnings Per Share. In the last year, the EPS has been growing by 77.14%, which is quite impressive.
BCRX shows a strong growth in Revenue. In the last year, the Revenue has grown by 45.85%.
The Revenue has been growing by 55.99% on average over the past years. This is a very strong growth!
EPS 1Y (TTM)77.14%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%166.67%
Revenue 1Y (TTM)45.85%
Revenue growth 3Y42.06%
Revenue growth 5Y55.99%
Sales Q2Q%49.41%
3.2 Future
BCRX is expected to show a strong growth in Earnings Per Share. In the coming years, the EPS will grow by 37.12% yearly.
Based on estimates for the next years, BCRX will show a quite strong growth in Revenue. The Revenue will grow by 13.80% on average per year.
EPS Next Y120.49%
EPS Next 2Y70.72%
EPS Next 3Y49.44%
EPS Next 5Y37.12%
Revenue Next Year39.07%
Revenue Next 2Y21.56%
Revenue Next 3Y17.53%
Revenue Next 5Y13.8%
3.3 Evolution
Although the future Revenue growth is still strong, it is not able to hold up the even more excellent growth rate of the past years.
4. Valuation
4.1 Price/Earnings Ratio
BCRX reported negative earnings for the last year, which makes the Price/Earnings Ratio negative.
With a Price/Forward Earnings ratio of 18.31, BCRX is valued on the expensive side.
BCRX's Price/Forward Earnings ratio is rather cheap when compared to the industry. BCRX is cheaper than 93.82% of the companies in the same industry.
BCRX is valuated rather cheaply when we compare the Price/Forward Earnings ratio to 22.99, which is the current average of the S&P500 Index.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| PE | N/A | ||
| Fwd PE | 18.31 |
4.2 Price Multiples
92.13% of the companies in the same industry are more expensive than BCRX, based on the Enterprise Value to EBITDA ratio.
90.45% of the companies in the same industry are more expensive than BCRX, based on the Price/Free Cash Flow ratio.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| P/FCF | 2156.21 | ||
| EV/EBITDA | 32.69 |
4.3 Compensation for Growth
BCRX's low PEG Ratio(NY), which compensates the Price/Earnings for growth, indicates a rather cheap valuation of the company.
A more expensive valuation may be justified as BCRX's earnings are expected to grow with 49.44% in the coming years.
PEG (NY)N/A
PEG (5Y)N/A
EPS Next 2Y70.72%
EPS Next 3Y49.44%
5. Dividend
5.1 Amount
BCRX does not give a dividend.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Dividend Yield | N/A |
7.2
+0.01 (+0.14%)
Chartmill FA Rating
GICS SectorHealth Care
GICS IndustryGroupPharmaceuticals, Biotechnology & Life Sciences
GICS IndustryBiotechnology
Earnings (Last)
Earnings (Next)
Inst Owners95.85%
Inst Owner Change-0.25%
Ins Owners0.59%
Ins Owner Change5.47%
Market Cap1.52B
Revenue(TTM)557.51M
Net Income(TTM)-35711000
Analysts83.53
Price Target17.99 (149.86%)
Short Float %13.29%
Short Ratio6.58
Dividend
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Dividend Yield | N/A |
Yearly DividendN/A
Dividend Growth(5Y)N/A
DPN/A
Div Incr Years0
Div Non Decr Years0
Ex-DateN/A
Surprises & Revisions
EPS beat(2)2
Avg EPS beat(2)140.06%
Min EPS beat(2)100%
Max EPS beat(2)180.11%
EPS beat(4)2
Avg EPS beat(4)37.5%
Min EPS beat(4)-123.6%
Max EPS beat(4)180.11%
EPS beat(8)5
Avg EPS beat(8)30.61%
EPS beat(12)7
Avg EPS beat(12)12.7%
EPS beat(16)9
Avg EPS beat(16)13.24%
Revenue beat(2)2
Avg Revenue beat(2)9.71%
Min Revenue beat(2)6.96%
Max Revenue beat(2)12.47%
Revenue beat(4)3
Avg Revenue beat(4)5.14%
Min Revenue beat(4)-0.92%
Max Revenue beat(4)12.47%
Revenue beat(8)6
Avg Revenue beat(8)4.56%
Revenue beat(12)7
Avg Revenue beat(12)2.76%
Revenue beat(16)8
Avg Revenue beat(16)1.37%
PT rev (1m)0%
PT rev (3m)0.52%
EPS NQ rev (1m)18.87%
EPS NQ rev (3m)-10.84%
EPS NY rev (1m)0.61%
EPS NY rev (3m)-21.93%
Revenue NQ rev (1m)0.53%
Revenue NQ rev (3m)3.94%
Revenue NY rev (1m)0.16%
Revenue NY rev (3m)2.22%
Valuation
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| PE | N/A | ||
| Fwd PE | 18.31 | ||
| P/S | 2.72 | ||
| P/FCF | 2156.21 | ||
| P/OCF | 861.75 | ||
| P/B | N/A | ||
| P/tB | N/A | ||
| EV/EBITDA | 32.69 |
EPS(TTM)-0.16
EYN/A
EPS(NY)0.39
Fwd EY5.46%
FCF(TTM)0
FCFY0.05%
OCF(TTM)0.01
OCFY0.12%
SpS2.65
BVpS-2
TBVpS-2
PEG (NY)N/A
PEG (5Y)N/A
Graham NumberN/A
Profitability
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| ROA | -7.81% | ||
| ROE | N/A | ||
| ROCE | 19.35% | ||
| ROIC | 15.29% | ||
| ROICexc | 214.19% | ||
| ROICexgc | 214.19% | ||
| OM | 9.72% | ||
| PM (TTM) | N/A | ||
| GM | 97% | ||
| FCFM | 0.13% |
ROA(3y)-35.62%
ROA(5y)-38.56%
ROE(3y)N/A
ROE(5y)N/A
ROIC(3y)N/A
ROIC(5y)N/A
ROICexc(3y)N/A
ROICexc(5y)N/A
ROICexgc(3y)N/A
ROICexgc(5y)N/A
ROCE(3y)N/A
ROCE(5y)N/A
ROICexgc growth 3YN/A
ROICexgc growth 5YN/A
ROICexc growth 3YN/A
ROICexc growth 5YN/A
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3Y0.65%
GM growth 5Y1.2%
F-Score5
Asset Turnover1.22
Health
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Debt/Equity | N/A | ||
| Debt/FCF | 1038.46 | ||
| Debt/EBITDA | 12.49 | ||
| Cap/Depr | 82.5% | ||
| Cap/Sales | 0.19% | ||
| Interest Coverage | 1.46 | ||
| Cash Conversion | 3.17% | ||
| Profit Quality | N/A | ||
| Current Ratio | 2.25 | ||
| Quick Ratio | 2.21 | ||
| Altman-Z | -2.18 |
F-Score5
WACC8.55%
ROIC/WACC1.79
Cap/Depr(3y)104.99%
Cap/Depr(5y)137.87%
Cap/Sales(3y)0.47%
Cap/Sales(5y)1.16%
Profit Quality(3y)N/A
Profit Quality(5y)N/A
High Growth Momentum
Growth
EPS 1Y (TTM)77.14%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%166.67%
EPS Next Y120.49%
EPS Next 2Y70.72%
EPS Next 3Y49.44%
EPS Next 5Y37.12%
Revenue 1Y (TTM)45.85%
Revenue growth 3Y42.06%
Revenue growth 5Y55.99%
Sales Q2Q%49.41%
Revenue Next Year39.07%
Revenue Next 2Y21.56%
Revenue Next 3Y17.53%
Revenue Next 5Y13.8%
EBIT growth 1Y189.85%
EBIT growth 3YN/A
EBIT growth 5YN/A
EBIT Next Year547.7%
EBIT Next 3Y123.29%
EBIT Next 5YN/A
FCF growth 1Y100.57%
FCF growth 3YN/A
FCF growth 5YN/A
OCF growth 1Y101.44%
OCF growth 3YN/A
OCF growth 5YN/A
BIOCRYST PHARMACEUTICALS INC / BCRX FAQ
Can you provide the ChartMill fundamental rating for BIOCRYST PHARMACEUTICALS INC?
ChartMill assigns a fundamental rating of 4 / 10 to BCRX.
What is the valuation status of BIOCRYST PHARMACEUTICALS INC (BCRX) stock?
ChartMill assigns a valuation rating of 6 / 10 to BIOCRYST PHARMACEUTICALS INC (BCRX). This can be considered as Fairly Valued.
Can you provide the profitability details for BIOCRYST PHARMACEUTICALS INC?
BIOCRYST PHARMACEUTICALS INC (BCRX) has a profitability rating of 4 / 10.
Can you provide the financial health for BCRX stock?
The financial health rating of BIOCRYST PHARMACEUTICALS INC (BCRX) is 4 / 10.